Abstract:Dementia is a worldwide concern. Its global prevalence is increasing. At present, there is no medication licensed to prevent or delay the onset of dementia. Inflammation has been suggested as a key factor in dementia pathogenesis. Therefore, medications with anti‐inflammatory properties could be beneficial for dementia prevention. To evaluate the effectiveness and adverse effects of aspirin and other non‐steroidal anti‐inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia. We searched ALOIS, the specialised register of the Cochrane Dementia and Cognitive Improvement Group up to 9 January 2020. ALOIS contains records of clinical trials identified from monthly searches of several major healthcare databases, trial registries and grey literature sources. We ran additional searches across MEDLINE (OvidSP), Embase (OvidSP) and six other databases to ensure that the searches were as comprehensive and up‐to‐date as possible. We also reviewed citations of reference lists of included studies. We searched for randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing aspirin or other NSAIDs with placebo for the primary or secondary prevention of dementia. We included trials with cognitively healthy participants (primary prevention) or participants with mild cognitive impairment (MCI) or cognitive complaints (secondary prevention). We used standard methodological procedures according to the Cochrane Handbook for Systematic Reviews of Interventions . We rated the strength of evidence for each outcome using the GRADE approach. We included four RCTs with 23,187 participants. Because of the diversity of these trials, we did not combine data to give summary estimates, but presented a narrative description of the evidence. We identified one trial (19,114 participants) comparing low‐dose aspirin (100 mg once daily) to placebo. Participants were aged 70 years or older with no history of dementia, cardiovascular disease or physical disability. Interim analysis indicated no significant treatment effect and the trial was terminated slightly early after a median of 4.7 years' follow‐up. There was no evidence of a difference in incidence of dementia between aspirin and placebo groups (risk ratio (RR) 0.98, 95% CI 0.83 to 1.15; high‐certainty evidence). Participants allocated aspirin had higher rates of major bleeding (RR 1.37, 95% CI 1.17 to 1.60, high‐certainty evidence) and slightly higher mortality (RR 1.14, 95% CI 1.01 to 1.28; high‐certainty evidence). There was no evidence of a difference in activities of daily living between groups (RR 0.84, 95% CI 0.70 to 1.02; high‐certainty evidence). We identified three trials comparing non‐aspirin NSAIDs to placebo. All three trials were terminated early due to adverse events associated with NSAIDs reported in other trials. One trial (2528 participants) investigated the cyclo‐oxygenase‐2 (COX‐2) inhibitor celecoxib (200 mg twice daily) and the non‐selective NSAID naproxen (220 mg twice daily) for preventing dementia in cognitively healthy older adults with a family history of Alzheimer's disease (AD). Median follow‐up was 734 days. Combining both NSAID treatment arms, there was no evidence of a difference in the incidence of AD between participants allocated NSAIDs and those allocated placebo (RR 1.91, 95% CI 0.89 to 4.10; moderate‐certainty evidence). There was also no evidence of a difference in rates of myocardial infarction (RR 1.21, 95% CI 0.61 to 2.40), stroke (RR 1.82, 95% CI 0.76 to 4.37) or mortality (RR 1.37, 95% CI 0.78 to 2.43) between treatment groups (all moderate‐certainty evidence). One trial (88 participants) assessed the effectiveness of celecoxib (200 mg or 400 mg daily) in delaying cognitive decline in participants aged 40 to 81 years with mild age‐related memory loss but normal memory performance scores. Mean duration of follow‐up was 17.6 months in the celecoxib group and 18.1 months in the placebo group. There was no evidence of a difference between groups in test scores in any of six cognitive domains. Participants allocated celecoxib experienced more gastrointestinal adverse events than those allocated placebo (RR 2.66, 95% CI 1.05 to 6.75; low‐certainty evidence). One trial (1457 participants) assessed the effectiveness of the COX‐2 inhibitor rofecoxib (25 mg once daily) in delaying or preventing a diagnosis of AD in participants with MCI. Median duration of study participation was 115 weeks in the rofecoxib group and 130 weeks in the placebo group. There was a higher incidence of AD in the rofecoxib than the placebo group (RR 1.32, 95% CI 1.01 to 1.72; moderate‐certainty evidence). There was no evidence of a difference between groups in cardiovascular adverse events (RR 1.07, 95% CI 0.68 to 1.66; moderate‐certainty evidence) or mortality (RR 1.62, 95% CI 0.85 to 3.05; moderate‐certainty evidence). Participants allocated rofecoxib had more upper -Abstract Truncated-

Does Stopping Aspirin Differ Fundamentally From Not Starting Aspirin in the Primary Prevention of Cardiovascular Disease Among Older Adults?

Primary prevention of myocardial infarction: aspirin is not as useful as it seems

Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis

Aspirin Resistance in the Elder Cardio-Cerebral-Vascular Diseases Patients

Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force

Aspirin for primary prevention of cardiovascular disease: a review of recent literature and updated guideline recommendations

Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease

Short- and long-term impact of aspirin cessation in older adults: a target trial emulation

A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial

Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People: Secondary Analysis of a Randomized Clinical Trial

Aspirin for primary prevention of stroke in individuals without cardiovascular disease—A meta-analysis

Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.

The Benefit and Safety of Aspirin for Primary Prevention of Ischemic Stroke: a Meta-Analysis of Randomized Trials

Effect of Aspirin on Cancer Incidence and Mortality in Older Adults

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease

Aspirin in the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis

Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries

Primary Prevention of Cardiovascular Disease in Older Adults

Daily low‐dose aspirin and blood pressure in community‐dwelling older adults

Abstract 326: De-escalation of Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease in the Primary Care Setting